CureGN Study Rationale, Design, and Methods : Establishing a Large Prospective Observational Study of Glomerular Disease
Copyright © 2018 National Kidney Foundation, Inc. All rights reserved..
RATIONALE & OBJECTIVES: Glomerular diseases, including minimal change disease, focal segmental glomerulosclerosis, membranous nephropathy, and immunoglobulin A (IgA) nephropathy, share clinical presentations, yet result from multiple biological mechanisms. Challenges to identifying underlying mechanisms, biomarkers, and new therapies include the rarity of each diagnosis and slow progression, often requiring decades to measure the effectiveness of interventions to prevent end-stage kidney disease (ESKD) or death.
STUDY DESIGN: Multicenter prospective cohort study.
SETTING & PARTICIPANTS: Cure Glomerulonephropathy (CureGN) will enroll 2,400 children and adults with minimal change disease, focal segmental glomerulosclerosis, membranous nephropathy, or IgA nephropathy (including IgA vasculitis) and a first diagnostic kidney biopsy within 5 years. Patients with ESKD and those with secondary causes of glomerular disease are excluded.
EXPOSURES: Clinical data, including medical history, medications, family history, and patient-reported outcomes, are obtained, along with a digital archive of kidney biopsy images and blood and urine specimens at study visits aligned with clinical care 1 to 4 times per year.
OUTCOMES: Patients are followed up for changes in estimated glomerular filtration rate, disease activity, ESKD, and death and for nonrenal complications of disease and treatment, including infection, malignancy, cardiovascular, and thromboembolic events.
ANALYTICAL APPROACH: The study design supports multiple longitudinal analyses leveraging the diverse data domains of CureGN and its ancillary program. At 2,400 patients and an average of 2 years' initial follow-up, CureGN has 80% power to detect an HR of 1.4 to 1.9 for proteinuria remission and a mean difference of 2.1 to 3.0mL/min/1.73m2 in estimated glomerular filtration rate per year.
LIMITATIONS: Current follow-up can only detect large differences in ESKD and death outcomes.
CONCLUSIONS: Study infrastructure will support a broad range of scientific approaches to identify mechanistically distinct subgroups, identify accurate biomarkers of disease activity and progression, delineate disease-specific treatment targets, and inform future therapeutic trials. CureGN is expected to be among the largest prospective studies of children and adults with glomerular disease, with a broad goal to lessen disease burden and improve outcomes.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:73 |
|---|---|
| Enthalten in: |
American journal of kidney diseases : the official journal of the National Kidney Foundation - 73(2019), 2 vom: 01. Feb., Seite 218-229 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Mariani, Laura H [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 12.11.2019 Date Revised 06.06.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1053/j.ajkd.2018.07.020 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM29052752X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM29052752X | ||
| 003 | DE-627 | ||
| 005 | 20231225064931.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1053/j.ajkd.2018.07.020 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0968.xml |
| 035 | |a (DE-627)NLM29052752X | ||
| 035 | |a (NLM)30420158 | ||
| 035 | |a (PII)S0272-6386(18)30936-3 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Mariani, Laura H |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a CureGN Study Rationale, Design, and Methods |b Establishing a Large Prospective Observational Study of Glomerular Disease |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 12.11.2019 | ||
| 500 | |a Date Revised 06.06.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2018 National Kidney Foundation, Inc. All rights reserved. | ||
| 520 | |a RATIONALE & OBJECTIVES: Glomerular diseases, including minimal change disease, focal segmental glomerulosclerosis, membranous nephropathy, and immunoglobulin A (IgA) nephropathy, share clinical presentations, yet result from multiple biological mechanisms. Challenges to identifying underlying mechanisms, biomarkers, and new therapies include the rarity of each diagnosis and slow progression, often requiring decades to measure the effectiveness of interventions to prevent end-stage kidney disease (ESKD) or death | ||
| 520 | |a STUDY DESIGN: Multicenter prospective cohort study | ||
| 520 | |a SETTING & PARTICIPANTS: Cure Glomerulonephropathy (CureGN) will enroll 2,400 children and adults with minimal change disease, focal segmental glomerulosclerosis, membranous nephropathy, or IgA nephropathy (including IgA vasculitis) and a first diagnostic kidney biopsy within 5 years. Patients with ESKD and those with secondary causes of glomerular disease are excluded | ||
| 520 | |a EXPOSURES: Clinical data, including medical history, medications, family history, and patient-reported outcomes, are obtained, along with a digital archive of kidney biopsy images and blood and urine specimens at study visits aligned with clinical care 1 to 4 times per year | ||
| 520 | |a OUTCOMES: Patients are followed up for changes in estimated glomerular filtration rate, disease activity, ESKD, and death and for nonrenal complications of disease and treatment, including infection, malignancy, cardiovascular, and thromboembolic events | ||
| 520 | |a ANALYTICAL APPROACH: The study design supports multiple longitudinal analyses leveraging the diverse data domains of CureGN and its ancillary program. At 2,400 patients and an average of 2 years' initial follow-up, CureGN has 80% power to detect an HR of 1.4 to 1.9 for proteinuria remission and a mean difference of 2.1 to 3.0mL/min/1.73m2 in estimated glomerular filtration rate per year | ||
| 520 | |a LIMITATIONS: Current follow-up can only detect large differences in ESKD and death outcomes | ||
| 520 | |a CONCLUSIONS: Study infrastructure will support a broad range of scientific approaches to identify mechanistically distinct subgroups, identify accurate biomarkers of disease activity and progression, delineate disease-specific treatment targets, and inform future therapeutic trials. CureGN is expected to be among the largest prospective studies of children and adults with glomerular disease, with a broad goal to lessen disease burden and improve outcomes | ||
| 650 | 4 | |a Comparative Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Observational Study | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a CureGN | |
| 650 | 4 | |a Glomerular disease | |
| 650 | 4 | |a Henoch-Schönlein purpura | |
| 650 | 4 | |a IgA nephropathy (IgAN) | |
| 650 | 4 | |a IgA vasculitis (IgAV) | |
| 650 | 4 | |a adult | |
| 650 | 4 | |a digital pathology repository | |
| 650 | 4 | |a estimated glomerular filtration rate (eGFR) | |
| 650 | 4 | |a focal segmental glomerulosclerosis (FSGS) | |
| 650 | 4 | |a glomerulonephropathy | |
| 650 | 4 | |a kidney biopsy | |
| 650 | 4 | |a longitudinal cohort | |
| 650 | 4 | |a membranous nephropathy (MN) | |
| 650 | 4 | |a minimal change disease (MCD) | |
| 650 | 4 | |a patient-reported outcome (PRO) | |
| 650 | 4 | |a pediatric | |
| 650 | 4 | |a study design | |
| 700 | 1 | |a Bomback, Andrew S |e verfasserin |4 aut | |
| 700 | 1 | |a Canetta, Pietro A |e verfasserin |4 aut | |
| 700 | 1 | |a Flessner, Michael F |e verfasserin |4 aut | |
| 700 | 1 | |a Helmuth, Margaret |e verfasserin |4 aut | |
| 700 | 1 | |a Hladunewich, Michelle A |e verfasserin |4 aut | |
| 700 | 1 | |a Hogan, Jonathan J |e verfasserin |4 aut | |
| 700 | 1 | |a Kiryluk, Krzysztof |e verfasserin |4 aut | |
| 700 | 1 | |a Nachman, Patrick H |e verfasserin |4 aut | |
| 700 | 1 | |a Nast, Cynthia C |e verfasserin |4 aut | |
| 700 | 1 | |a Rheault, Michelle N |e verfasserin |4 aut | |
| 700 | 1 | |a Rizk, Dana V |e verfasserin |4 aut | |
| 700 | 1 | |a Trachtman, Howard |e verfasserin |4 aut | |
| 700 | 1 | |a Wenderfer, Scott E |e verfasserin |4 aut | |
| 700 | 1 | |a Bowers, Corinna |e verfasserin |4 aut | |
| 700 | 1 | |a Hill-Callahan, Peg |e verfasserin |4 aut | |
| 700 | 1 | |a Marasa, Maddalena |e verfasserin |4 aut | |
| 700 | 1 | |a Poulton, Caroline J |e verfasserin |4 aut | |
| 700 | 1 | |a Revell, Adelaide |e verfasserin |4 aut | |
| 700 | 1 | |a Vento, Suzanne |e verfasserin |4 aut | |
| 700 | 1 | |a Barisoni, Laura |e verfasserin |4 aut | |
| 700 | 1 | |a Cattran, Dan |e verfasserin |4 aut | |
| 700 | 1 | |a D'Agati, Vivette |e verfasserin |4 aut | |
| 700 | 1 | |a Jennette, J Charles |e verfasserin |4 aut | |
| 700 | 1 | |a Klein, Jon B |e verfasserin |4 aut | |
| 700 | 1 | |a Laurin, Louis-Philippe |e verfasserin |4 aut | |
| 700 | 1 | |a Twombley, Katherine |e verfasserin |4 aut | |
| 700 | 1 | |a Falk, Ronald J |e verfasserin |4 aut | |
| 700 | 1 | |a Gharavi, Ali G |e verfasserin |4 aut | |
| 700 | 1 | |a Gillespie, Brenda W |e verfasserin |4 aut | |
| 700 | 1 | |a Gipson, Debbie S |e verfasserin |4 aut | |
| 700 | 1 | |a Greenbaum, Larry A |e verfasserin |4 aut | |
| 700 | 1 | |a Holzman, Lawrence B |e verfasserin |4 aut | |
| 700 | 1 | |a Kretzler, Matthias |e verfasserin |4 aut | |
| 700 | 1 | |a Robinson, Bruce |e verfasserin |4 aut | |
| 700 | 1 | |a Smoyer, William E |e verfasserin |4 aut | |
| 700 | 1 | |a Guay-Woodford, Lisa M |e verfasserin |4 aut | |
| 700 | 0 | |a CureGN Consortium |e verfasserin |4 aut | |
| 700 | 1 | |a Ahn, Wooin |e investigator |4 oth | |
| 700 | 1 | |a Appel, Gerald B |e investigator |4 oth | |
| 700 | 1 | |a Babayev, Revekka |e investigator |4 oth | |
| 700 | 1 | |a Batal, Ibrahim |e investigator |4 oth | |
| 700 | 1 | |a Bomback, Andrew S |e investigator |4 oth | |
| 700 | 1 | |a Brown, Eric |e investigator |4 oth | |
| 700 | 1 | |a Campenot, Eric S |e investigator |4 oth | |
| 700 | 1 | |a Canetta, Pietro |e investigator |4 oth | |
| 700 | 1 | |a Carlassara, Lucrezia |e investigator |4 oth | |
| 700 | 1 | |a Chan, Brenda |e investigator |4 oth | |
| 700 | 1 | |a Chatterjee, Debanjana |e investigator |4 oth | |
| 700 | 1 | |a D'Agati, Vivette D |e investigator |4 oth | |
| 700 | 1 | |a Delbarba, Elisa |e investigator |4 oth | |
| 700 | 1 | |a Dogra, Samriti |e investigator |4 oth | |
| 700 | 1 | |a Fernandez, Hilda |e investigator |4 oth | |
| 700 | 1 | |a Foroncewicz, Bartosz |e investigator |4 oth | |
| 700 | 1 | |a Gharavi, Ali G |e investigator |4 oth | |
| 700 | 1 | |a Ghiggeri, Gian Marco |e investigator |4 oth | |
| 700 | 1 | |a Hines, William H |e investigator |4 oth | |
| 700 | 1 | |a Ali Husain, S |e investigator |4 oth | |
| 700 | 1 | |a Jain, Namrata G |e investigator |4 oth | |
| 700 | 1 | |a Khairallah, Pascale |e investigator |4 oth | |
| 700 | 1 | |a Kil, Byum Hee |e investigator |4 oth | |
| 700 | 1 | |a Kiryluk, Krzysztof |e investigator |4 oth | |
| 700 | 1 | |a Jeyabalan, Anushya |e investigator |4 oth | |
| 700 | 1 | |a Lau, Wai L |e investigator |4 oth | |
| 700 | 1 | |a Lin, Fangming |e investigator |4 oth | |
| 700 | 1 | |a Lugani, Francesca |e investigator |4 oth | |
| 700 | 1 | |a Marasa, Maddalena |e investigator |4 oth | |
| 700 | 1 | |a Markowitz, Glen |e investigator |4 oth | |
| 700 | 1 | |a Mohan, Sumit |e investigator |4 oth | |
| 700 | 1 | |a Mu, Xueru |e investigator |4 oth | |
| 700 | 1 | |a Mucha, Krzysztof |e investigator |4 oth | |
| 700 | 1 | |a Nickolas, Thomas L |e investigator |4 oth | |
| 700 | 1 | |a Piva, Stacy |e investigator |4 oth | |
| 700 | 1 | |a Radhakrishnan, Jai |e investigator |4 oth | |
| 700 | 1 | |a Rao, Maya K |e investigator |4 oth | |
| 700 | 1 | |a Regunathan-Shenk, Renu |e investigator |4 oth | |
| 700 | 1 | |a Sanna-Cherchi, Simone |e investigator |4 oth | |
| 700 | 1 | |a Santoriello, Dominick |e investigator |4 oth | |
| 700 | 1 | |a Shirazian, Shayan |e investigator |4 oth | |
| 700 | 1 | |a Stokes, Michael B |e investigator |4 oth | |
| 700 | 1 | |a Yu, Natalie |e investigator |4 oth | |
| 700 | 1 | |a Valeri, Anthony M |e investigator |4 oth | |
| 700 | 1 | |a Zviti, Ronald |e investigator |4 oth | |
| 700 | 1 | |a Greenbaum, Larry A |e investigator |4 oth | |
| 700 | 1 | |a Smoyer, William E |e investigator |4 oth | |
| 700 | 1 | |a Al-Uzri, Amira |e investigator |4 oth | |
| 700 | 1 | |a Ambruzs, Josephine |e investigator |4 oth | |
| 700 | 1 | |a Ashoor, Isa |e investigator |4 oth | |
| 700 | 1 | |a Aviles, Diego |e investigator |4 oth | |
| 700 | 1 | |a Baracco, Rossana |e investigator |4 oth | |
| 700 | 1 | |a Barcia, John |e investigator |4 oth | |
| 700 | 1 | |a Bartosh, Sharon |e investigator |4 oth | |
| 700 | 1 | |a Belsha, Craig |e investigator |4 oth | |
| 700 | 1 | |a Bowers, Corinna |e investigator |4 oth | |
| 700 | 1 | |a Braun, Michael C |e investigator |4 oth | |
| 700 | 1 | |a Cai, Yi |e investigator |4 oth | |
| 700 | 1 | |a Chernitskiy, Vladimir |e investigator |4 oth | |
| 700 | 1 | |a Chishti, Aftab |e investigator |4 oth | |
| 700 | 1 | |a Claes, Donna |e investigator |4 oth | |
| 700 | 1 | |a Clark, Kira |e investigator |4 oth | |
| 700 | 1 | |a Cramer, Carl |e investigator |4 oth | |
| 700 | 1 | |a Davis, Keefe |e investigator |4 oth | |
| 700 | 1 | |a Dutcher, Amy |e investigator |4 oth | |
| 700 | 1 | |a Erkan, Elif |e investigator |4 oth | |
| 700 | 1 | |a Feig, Daniel |e investigator |4 oth | |
| 700 | 1 | |a Freundlich, Michael |e investigator |4 oth | |
| 700 | 1 | |a Gaut, Joseph |e investigator |4 oth | |
| 700 | 1 | |a Gbadegesin, Rasheed |e investigator |4 oth | |
| 700 | 1 | |a Hanna, Melisha |e investigator |4 oth | |
| 700 | 1 | |a Hidalgo, Guillermo |e investigator |4 oth | |
| 700 | 1 | |a Hooper, David |e investigator |4 oth | |
| 700 | 1 | |a Hunley, Tracy E |e investigator |4 oth | |
| 700 | 1 | |a Jain, Amrish |e investigator |4 oth | |
| 700 | 1 | |a Kallash, Mahmoud |e investigator |4 oth | |
| 700 | 1 | |a Kamel, Margo |e investigator |4 oth | |
| 700 | 1 | |a Khalid, Myda |e investigator |4 oth | |
| 700 | 1 | |a Klein, Jon B |e investigator |4 oth | |
| 700 | 1 | |a Kump, Theresa |e investigator |4 oth | |
| 700 | 1 | |a Lane, Jerome C |e investigator |4 oth | |
| 700 | 1 | |a Liapis, Helen |e investigator |4 oth | |
| 700 | 1 | |a Mahan, John |e investigator |4 oth | |
| 700 | 1 | |a Mathews, Nisha |e investigator |4 oth | |
| 700 | 1 | |a Nester, Carla |e investigator |4 oth | |
| 700 | 1 | |a Pan, Cynthia |e investigator |4 oth | |
| 700 | 1 | |a Patterson, Larry |e investigator |4 oth | |
| 700 | 1 | |a Patel, Hiren |e investigator |4 oth | |
| 700 | 1 | |a Raad, Alice |e investigator |4 oth | |
| 700 | 1 | |a Revell, Adelaide |e investigator |4 oth | |
| 700 | 1 | |a Rheault, Michelle N |e investigator |4 oth | |
| 700 | 1 | |a Silva, Cynthia |e investigator |4 oth | |
| 700 | 1 | |a Sreedharan, Rajasree |e investigator |4 oth | |
| 700 | 1 | |a Srivastava, Tarak |e investigator |4 oth | |
| 700 | 1 | |a Steinke, Julia |e investigator |4 oth | |
| 700 | 1 | |a Sumner, Susan |e investigator |4 oth | |
| 700 | 1 | |a Twombley, Katherine |e investigator |4 oth | |
| 700 | 1 | |a Wenderfer, Scott E |e investigator |4 oth | |
| 700 | 1 | |a Vasylyeva, Tetyana L |e investigator |4 oth | |
| 700 | 1 | |a Wang, Chia-Shi |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t American journal of kidney diseases : the official journal of the National Kidney Foundation |d 1982 |g 73(2019), 2 vom: 01. Feb., Seite 218-229 |w (DE-627)NLM012600814 |x 1523-6838 |7 nnns |
| 773 | 1 | 8 | |g volume:73 |g year:2019 |g number:2 |g day:01 |g month:02 |g pages:218-229 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1053/j.ajkd.2018.07.020 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 73 |j 2019 |e 2 |b 01 |c 02 |h 218-229 | ||